Options for Increasing Access to Medicines in the Developing World

May 1 2010
In response to requests from its members, BIO has developed a formal BIO Policy Statement on Options for Increasing Access to Medicines in the Developing World to help educate members on the issue.

Pesticide Labeling: BIO Opposes EPA Wording of PPVR Label

Apr 30 2010

Cloning: Letter to USTR from BIO, AMI, NCBA, NMA and NPPC

Apr 23 2010

Letter urging countries to treat progeny of clones entering the food supply in both foreign and domestic markets as equivalent to conventionally raised animals.

Plant Biotechnology: Food Derived From New Plant Varieties

Apr 19 2010

BIO’s April 19, 2010 comments to FDA RE: "Consultation Procedures: Foods Derived From New Plant Varieties" 75 Fed. Reg. 7274.

BIO’s comments to the EPA regarding proposed language on labeling for the Coat Protein Gene of Plum Pox Virus point out that directions for use in organic agriculture do not fall under FIFRA regulation.

Apr 15 2010


Food and Drug Administration: BIO Comments on FDA Transparency Initiative

Apr 12 2010


Reauthorization of the Prescription Drug User Fee Act (PDUFA)

Apr 12 2010
BIO's comments support the reauthorization of PDUFA and discuss how to ensure achievement of the goals envisioned as well as considering what refinements might be made in order to achieve those goals.

Clear, consistent and open communication with the public and regulated industry, conducted in a manner that balances the importance of protecting competitive commercial information, is a critical FDA function.

Apr 9 2010


BIO Letters of Support for Funding for the Cures Acceleration Network (CAN)

Apr 7 2010

Letters expressing support for $500 million in funding for CAN for FY2011.

BIO Policy Statement: Options for Increasing Access to Medicines in the Developing World

Apr 1 2010
Biotechnology plays a critical role in saving lives and improving the quality of life for millions of people throughout the world. It provides useful tools for combating disease, hunger, climate change, and other environmental impacts. The Biotechnology Industry Organization (BIO) is committed to addressing these global changes. BIO represents biotechnology companies, academic institutions, state biotechnology centers, venture capital firms, and related organizations throughout the United States and in 30 countries.